AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 3309479 — intervention group
Group type: COMPARATOR
Intervention: Group II (two-dose protocol): 75% of the calculated protamine dose infused within 10 minutes after termination of bypass, remainder after transfusion of all blood in the heart-lung machine.
Number of subjects: 20
Study 29777714 — intervention group
Group type: EXPERIMENTAL
Intervention: NMES (15Hz, pulse width 200μs) applied to supraspinatus and deltoids for 4 weeks, 20 sessions of 1 hour each.
Number of subjects: 90
Study 29777714 — intervention group
Group type: EXPERIMENTAL
Intervention: TENS (100Hz, pulse width 100μs) used on the same areas for 4 weeks, 20 sessions of 1 hour each.
Number of subjects: 90
Study 29777714 — intervention group
Group type: COMPARATOR
Intervention: Control group received routine rehabilitation without stimulation.
Number of subjects: 90
Study 27228512 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 0.5 µg/kg (DEX I group)
Number of subjects: 120
Study 27228512 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 0.3 µg/kg (DEX II group)
Number of subjects: 120
Study 27228512 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 0.2 µg/kg (DEX III group)
Number of subjects: 120
Study 27228512 — intervention group
Group type: COMPARATOR
Intervention: Meperidine 0.4 mg/kg (meperidine group)
Number of subjects: 120
Study 24286284 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic repair (LR)
Number of subjects: 62
Study 24286284 — intervention group
Group type: COMPARATOR
Intervention: Open repair (OR)
Number of subjects: 62
Study 22353612 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidant cocktail (vitamin C, 1000 mg; vitamin E, 600 IU; α‐lipoic acid, 600 mg)
Number of subjects: 87
Study 22353612 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 87
Study 19826827 — intervention group
Group type: EXPERIMENTAL
Intervention: Voice training program for 4 weeks
Number of subjects: 0
Study 18953651 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemoendocrine treatment
Number of subjects: 893
Study 18953651 — intervention group
Group type: COMPARATOR
Intervention: Endocrine therapy (ET) alone
Number of subjects: 893
Study 18953651 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Number of subjects: 893
Study 15842141 — intervention group
Group type: EXPERIMENTAL
Intervention: Aitongping capsule (ATP)
Number of subjects: 60
Study 15842141 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac (Control)
Number of subjects: 60
Study 12851275 — intervention group
Group type: EXPERIMENTAL
Intervention: Promensil (82 mg of total isoflavones per day)
Number of subjects: 252
Study 12851275 — intervention group
Group type: EXPERIMENTAL
Intervention: Rimostil (57 mg of total isoflavones per day)
Number of subjects: 252
Study 12851275 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 252
Study 10229276 — intervention group
Group type: EXPERIMENTAL
Intervention: Silicone insert
Number of subjects: 236
Study 10229276 — intervention group
Group type: EXPERIMENTAL
Intervention: Rubber insert
Number of subjects: 236
Study 10229276 — intervention group
Group type: EXPERIMENTAL
Intervention: Felt insert
Number of subjects: 236
Study 10229276 — intervention group
Group type: COMPARATOR
Intervention: Stretching only
Number of subjects: 236
Study 10229276 — intervention group
Group type: EXPERIMENTAL
Intervention: Custom orthosis
Number of subjects: 236
Study 8707387 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcendental Meditation
Number of subjects: 127
Study 8707387 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive Muscle Relaxation
Number of subjects: 127
Study 1746418 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral controlled-release mononitrate for 1 month
Number of subjects: 10000
Study 1746418 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral captopril for 1 month
Number of subjects: 10000
Study 1746418 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous magnesium for 24 hours
Number of subjects: 10000
Study 1746418 — intervention group
Group type: COMPARATOR
Intervention: Placebo for oral controlled-release mononitrate
Number of subjects: 10000
Study 1746418 — intervention group
Group type: COMPARATOR
Intervention: Placebo for oral captopril
Number of subjects: 10000
Study 1746418 — intervention group
Group type: COMPARATOR
Intervention: Open control (no infusion) for intravenous magnesium
Number of subjects: 10000
Study 6137945 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta blockers (e.g., practolol, timolol, propranolol)
Number of subjects: 8000
Study 6137945 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol (Norwegian Multicenter Study)
Number of subjects: 8000
Study 6137945 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (Beta‐Blocker Heart Attack Trial)
Number of subjects: 8000
Study 30694523 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab with neoadjuvant chemotherapy (NCT)
Number of subjects: 1160
Study 30694523 — intervention group
Group type: COMPARATOR
Intervention: Neoadjuvant chemotherapy (NCT)
Number of subjects: 1160
Study 30477773 — intervention group
Group type: EXPERIMENTAL
Intervention: Miniscrews
Number of subjects: 80
Study 30477773 — intervention group
Group type: COMPARATOR
Intervention: Molar blocks
Number of subjects: 80
Study 26497831 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil supplementation providing 1400 mg per day EPA+DHA
Number of subjects: 261
Study 26497831 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 261
Study 24003005 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental Group (EG) - summary of family psychosocial risk information provided to the medical team
Number of subjects: 67
Study 24003005 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG) - no summary of family psychosocial risk information provided
Number of subjects: 67
Study 23134960 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical stimulation of auricular Shenmen point (group A)
Number of subjects: 180
Study 23134960 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical stimulation of auricular Eye point (group B)
Number of subjects: 180
Study 23134960 — intervention group
Group type: COMPARATOR
Intervention: Control group (group C)
Number of subjects: 180
Study 20872127 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser acupuncture
Number of subjects: 111
Study 20872127 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 111
Study 17465862 — intervention group
Group type: EXPERIMENTAL
Intervention: LT4/LT3 combined therapy
Number of subjects: 20
Study 17465862 — intervention group
Group type: COMPARATOR
Intervention: LT4 monotherapy
Number of subjects: 20
Study 15284043 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical abortions performed by physician assistants
Number of subjects: 1363
Study 15284043 — intervention group
Group type: COMPARATOR
Intervention: Surgical abortions performed by physicians
Number of subjects: 1363
Study 15284043 — intervention group
Group type: EXPERIMENTAL
Intervention: History of pelvic inflammatory disease
Number of subjects: 1363
Study 11487166 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 g of amoxicillin
Number of subjects: 70
Study 11487166 — intervention group
Group type: COMPARATOR
Intervention: 3 g of placebo control
Number of subjects: 70
Study 9921941 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative radiochemotherapy
Number of subjects: 1104
Study 9921941 — intervention group
Group type: COMPARATOR
Intervention: Adjuvant radiotherapy
Number of subjects: 1104
Study 9921941 — intervention group
Group type: COMPARATOR
Intervention: Conventional radiochemotherapy
Number of subjects: 1104
Study 9921941 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative radiotherapy (IORT)
Number of subjects: 1104
Study 7917898 — intervention group
Group type: EXPERIMENTAL
Intervention: Death-education course
Number of subjects: 168
Study 7917898 — intervention group
Group type: COMPARATOR
Intervention: Control group (freshman students not taking the course)
Number of subjects: 168
Study 7917898 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined groups (course attendees and controls)
Number of subjects: 168
Study 3294124 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy with cimetidine 1 g daily and cisapride 40 mg daily
Number of subjects: 47
Study 3294124 — intervention group
Group type: COMPARATOR
Intervention: Single drug therapy (cimetidine and placebo)
Number of subjects: 47
Study 3294124 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy with cimetidine + cisapride
Number of subjects: 47
Study 31567794 — intervention group
Group type: EXPERIMENTAL
Intervention: Acemannan sponge graft
Number of subjects: 30
Study 31567794 — intervention group
Group type: COMPARATOR
Intervention: Blood clot control
Number of subjects: 30
Study 28651586 — intervention group
Group type: EXPERIMENTAL
Intervention: OncoActive intervention (computer-tailored physical activity program)
Number of subjects: 428
Study 28651586 — intervention group
Group type: COMPARATOR
Intervention: Usual care waiting-list control group
Number of subjects: 428
Study 26025245 — intervention group
Group type: EXPERIMENTAL
Intervention: ICG-(99m)Tc-nanocolloid
Number of subjects: 40
Study 26025245 — intervention group
Group type: COMPARATOR
Intervention: (99m)Tc-nanocolloid
Number of subjects: 40
Study 24355343 — intervention group
Group type: EXPERIMENTAL
Intervention: Active telephone-based recruitment strategy (email invitation and 1 to 3 follow-up phone calls)
Number of subjects: 128
Study 24355343 — intervention group
Group type: COMPARATOR
Intervention: Passive recruitment strategy (informed via newsletters)
Number of subjects: 128
Study 21765368 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg once daily for 7 days with fimasartan 240 mg
Number of subjects: 24
Study 21765368 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin 80 mg once daily for 7 days
Number of subjects: 24
Study 19835119 — intervention group
Group type: EXPERIMENTAL
Intervention: Warming needling treatment combined with cupping (needle inserted on sciatic nerve at Huantiao (GB 30))
Number of subjects: 150
Study 19835119 — intervention group
Group type: COMPARATOR
Intervention: Warming needling treatment combined with cupping (needle not needled on sciatic nerve)
Number of subjects: 150
Study 17342038 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-eluting stents (DES)
Number of subjects: 0
Study 17342038 — intervention group
Group type: COMPARATOR
Intervention: Bare metal stents (BMS)
Number of subjects: 0
Study 15008676 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants trained with features
Number of subjects: 0
Study 15008676 — intervention group
Group type: EXPERIMENTAL
Intervention: Transformation tests
Number of subjects: 0
Study 15008676 — intervention group
Group type: EXPERIMENTAL
Intervention: Removal of features at correct and geometrically equivalent corners
Number of subjects: 0
Study 11563999 — intervention group
Group type: EXPERIMENTAL
Intervention: Rofecoxib 25 mg
Number of subjects: 1516
Study 11563999 — intervention group
Group type: EXPERIMENTAL
Intervention: Rofecoxib 50 mg
Number of subjects: 1516
Study 11563999 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen 2400 mg daily
Number of subjects: 1516
Study 11563999 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1516
Study 11563999 — intervention group
Group type: EXPERIMENTAL
Intervention: H. pylori infection
Number of subjects: 1516
Study 9700954 — intervention group
Group type: COMPARATOR
Intervention: Hyperglycemia (15 mM)
Number of subjects: 7
Study 9700954 — intervention group
Group type: EXPERIMENTAL
Intervention: Bombesin infusion (1 ng/kg x min) during hyperglycemia
Number of subjects: 7
Study 7716349 — intervention group
Group type: EXPERIMENTAL
Intervention: Bamiphylline (600 mg b.d. for 15 days)
Number of subjects: 20
Study 7716349 — intervention group
Group type: COMPARATOR
Intervention: Placebo (600 mg b.d. for 15 days)
Number of subjects: 20
Study 2528737 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoladex + flutamide
Number of subjects: 0
Study 2528737 — intervention group
Group type: COMPARATOR
Intervention: Zoladex
Number of subjects: 0
Study 861125 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutethimide
Number of subjects: 5
Study 861125 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrazepam
Number of subjects: 5
Study 861125 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study 31079080 — intervention group
Group type: EXPERIMENTAL
Intervention: £20 activity enabling vouchers every month for a year
Number of subjects: 64
Study 31079080 — intervention group
Group type: EXPERIMENTAL
Intervention: Support worker
Number of subjects: 64
Study 31079080 — intervention group
Group type: EXPERIMENTAL
Intervention: Trained peer mentor
Number of subjects: 64
Study 29096157 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Number of subjects: 0
Study 29096157 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 25462653 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief Strategic Family Therapy (BSFT)
Number of subjects: 480
Study 25462653 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 480
Study 24512796 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with MS
Number of subjects: 53
Study 22496775 — intervention group
Group type: EXPERIMENTAL
Intervention: Ad5 seropositive participants who later acquired HIV
Number of subjects: 0
Study 22496775 — intervention group
Group type: EXPERIMENTAL
Intervention: Ad35 seropositivity
Number of subjects: 0
Study 22496775 — intervention group
Group type: COMPARATOR
Intervention: Ad5 seropositive participants
Number of subjects: 0
Study 22496775 — intervention group
Group type: EXPERIMENTAL
Intervention: Ad5 seronegative subjects
Number of subjects: 0
Study 19841526 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline (5mg/kg)
Number of subjects: 36
Study 19841526 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 17563596 — intervention group
Group type: EXPERIMENTAL
Intervention: Nursing education program
Number of subjects: 841
Study 15453517 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 0
Study 15453517 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam
Number of subjects: 0
Study 15453517 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 11339586 — intervention group
Group type: EXPERIMENTAL
Intervention: Mersilene mesh
Number of subjects: 56
Study 11339586 — intervention group
Group type: COMPARATOR
Intervention: Autogenous fascia lata
Number of subjects: 56
Study 9701388 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (i.v.Ig) prophylaxis
Number of subjects: 633
Study 9701388 — intervention group
Group type: COMPARATOR
Intervention: Control (no i.v.Ig)
Number of subjects: 633
Study 8017316 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem CD (DCD) 60 mg
Number of subjects: 227
Study 8017316 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem CD (DCD) 120 mg
Number of subjects: 227
Study 8017316 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem CD (DCD) 240 mg
Number of subjects: 227
Study 8017316 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem CD (DCD) 360 mg
Number of subjects: 227
Study 8017316 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem CD (DCD) 480 mg
Number of subjects: 227
Study 8017316 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem CD (DCD)
Number of subjects: 227
Study 8017316 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 227
Study 2400071 — intervention group
Group type: EXPERIMENTAL
Intervention: Brain laryngeal mask airway
Number of subjects: 100
Study 2400071 — intervention group
Group type: COMPARATOR
Intervention: Guedel oral airway
Number of subjects: 100
Study 71602 — intervention group
Group type: EXPERIMENTAL
Intervention: (−)‐deprenyl 10 mg daily or on alternate days
Number of subjects: 41
Study 71602 — intervention group
Group type: EXPERIMENTAL
Intervention: (−)‐deprenyl
Number of subjects: 41
Study 71602 — intervention group
Group type: EXPERIMENTAL
Intervention: (−)‐deprenyl with levodopa and carbidopa
Number of subjects: 41
Study 71602 — intervention group
Group type: EXPERIMENTAL
Intervention: (−)‐deprenyl with smaller total daily doses of levodopa and a peripheral decarboxylase inhibitor
Number of subjects: 41
Study 30942013 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradermal needling after pterygium resection
Number of subjects: 76
Study 30942013 — intervention group
Group type: COMPARATOR
Intervention: Control group (only pterygium resection)
Number of subjects: 76
Study 29423177 — intervention group
Group type: COMPARATOR
Intervention: Neonatal vitamin A supplementation (placebo-controlled)
Number of subjects: 10644
Study 26315154 — intervention group
Group type: EXPERIMENTAL
Intervention: VIP ON (Ventricular Intrinsic Preference algorithm)
Number of subjects: 389
Study 26315154 — intervention group
Group type: COMPARATOR
Intervention: VIP OFF (Control group)
Number of subjects: 389
Study 26315154 — intervention group
Group type: EXPERIMENTAL
Intervention: VIP ON
Number of subjects: 389
Study 26315154 — intervention group
Group type: COMPARATOR
Intervention: VIP OFF
Number of subjects: 389
Study 23137103 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (1%) administered at a dose of 3 mg·kg(‐1) intravenously, maintained by propofol infusion (0.5%) at 12 mg·kg(‐1·) h(‐1) for the first 20 min and at 8 mg·kg(‐1·) h(‐1) thereafter
Number of subjects: 0
Study 21450602 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity interval training for 6 months
Number of subjects: 40
Study 21450602 — intervention group
Group type: COMPARATOR
Intervention: Control group (no exercise training)
Number of subjects: 40
Study 21450602 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity interval training
Number of subjects: 40
Study 19336356 — intervention group
Group type: EXPERIMENTAL
Intervention: Environmental and educational intervention promoting water consumption (water fountains installed, 4 classroom lessons)
Number of subjects: 2950
Study 19336356 — intervention group
Group type: EXPERIMENTAL
Intervention: Environmental and educational intervention promoting water consumption
Number of subjects: 2950
Study 19336356 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 2950
Study 16564939 — intervention group
Group type: EXPERIMENTAL
Intervention: Morning hemodialysis
Number of subjects: 1845
Study 16564939 — intervention group
Group type: COMPARATOR
Intervention: Midday hemodialysis
Number of subjects: 1845
Study 16373890 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise (75-min session consisting of four 15-min periods of walking on a treadmill to a target heart rate of 140 bpm and three 5-min rest periods)
Number of subjects: 50
Study 16373890 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Number of subjects: 50
Study 16373890 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment of hypoglycemia with 15 g of oral glucose
Number of subjects: 50
Study 12727976 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth Hormone (GH) 0.043 mg/kg x d
Number of subjects: 12
Study 12727976 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 10483950 — intervention group
Group type: EXPERIMENTAL
Intervention: Suboptimal stenting
Number of subjects: 265
Study 10483950 — intervention group
Group type: COMPARATOR
Intervention: Optimal stenting
Number of subjects: 265
Study 8607484 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol 200 micrograms q.i.d.
Number of subjects: 374
Study 8607484 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine 150 mg b.i.d.
Number of subjects: 374
Study 1752708 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (5 mg/kg)
Number of subjects: 6
Study 1752708 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 7064012 — intervention group
Group type: EXPERIMENTAL
Intervention: Tizolemide 100 mg
Number of subjects: 16
Study 7064012 — intervention group
Group type: EXPERIMENTAL
Intervention: Furosemide 80 mg
Number of subjects: 16
Study 7064012 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 30365255 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) combined with multi‐mode analgesia
Number of subjects: 40
Study 30365255 — intervention group
Group type: COMPARATOR
Intervention: Simple multi‐mode analgesia (Control)
Number of subjects: 40
Study 27823868 — intervention group
Group type: COMPARATOR
Intervention: Saxagliptin
Number of subjects: 720
Study 27823868 — intervention group
Group type: COMPARATOR
Intervention: Glimepiride
Number of subjects: 720
Study 27823868 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 720
Study 25742759 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg losartan
Number of subjects: 3843
Study 25742759 — intervention group
Group type: COMPARATOR
Intervention: 50 mg losartan
Number of subjects: 3843
Study 25742759 — intervention group
Group type: EXPERIMENTAL
Intervention: Increase in SCr >0.3 mg/dl
Number of subjects: 3843
Study 25742759 — intervention group
Group type: EXPERIMENTAL
Intervention: Increase in SCr >0.3 mg/dl before 4 months
Number of subjects: 3843
Study 23763558 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% articaine with 1:100,000 epinephrine
Number of subjects: 30
Study 23763558 — intervention group
Group type: COMPARATOR
Intervention: 4% articaine with 1:200,000 epinephrine
Number of subjects: 30
Study 20622687 — intervention group
Group type: EXPERIMENTAL
Intervention: Clevidipine (0.5 mg/mL in 20% lipid solution, initiated at 10 mg/h and titrated to effect)
Number of subjects: 22
Study 16944000 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual reality (VR) simulation training, practiced two times over 3 weeks, 40 minutes each session.
Number of subjects: 77
Study 16944000 — intervention group
Group type: COMPARATOR
Intervention: Traditional class attendance (control group).
Number of subjects: 77
Study 16944000 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual reality (VR) simulation training.
Number of subjects: 77
Study 16874784 — intervention group
Group type: EXPERIMENTAL
Intervention: Knee pain
Number of subjects: 6641
Study 16874784 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinician diagnosis of knee OA
Number of subjects: 6641
Study 12634464 — intervention group
Group type: EXPERIMENTAL
Intervention: (153)Sm‐EDTMP
Number of subjects: 18
Study 12634464 — intervention group
Group type: COMPARATOR
Intervention: pamidronate disodium
Number of subjects: 18